{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:26:16Z","timestamp":1785803176349,"version":"3.56.0"},"reference-count":122,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA174861"],"award-info":[{"award-number":["R01CA174861"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228760"],"award-info":[{"award-number":["R01CA228760"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Russian Ministry of Science and Higher Education","award":["FSUS-2020-0035"],"award-info":[{"award-number":["FSUS-2020-0035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Adenovirus vectors are the most frequently used agents for gene therapy, including oncolytic therapy and vaccine development. It\u2019s hard to overestimate the value of adenoviruses during the COVID-19 pandemic as to date four out of four approved viral vector-based SARS-CoV-2 vaccines are developed on adenovirus platform. The vast majority of adenoviral vectors are based on the most studied human adenovirus type 5 (HAdV-C5), however, its immunogenicity often hampers the clinical translation of HAdV-C5 vectors. The search of less seroprevalent adenovirus types led to another species C adenovirus, Adenovirus type 6 (HAdV-C6). HAdV-C6 possesses high oncolytic efficacy against multiple cancer types and remarkable ability to induce the immune response towards carrying antigens. Being genetically very close to HAdV-C5, HAdV-C6 differs from HAdV-C5 in structure of the most abundant capsid protein, hexon. This leads to the ability of HAdV-C6 to evade the uptake by Kupffer cells as well as to distinct opsonization by immunoglobulins and other blood proteins, influencing the overall biodistribution of HAdV-C6 after systemic administration. This review describes the structural features of HAdV-C6, its interaction with liver cells and blood factors, summarizes the previous experiences using HAdV-C6, and provides the rationale behind the use of HAdV-C6 for vaccine and anticancer drugs developments.<\/jats:p>","DOI":"10.3390\/pharmaceutics13101641","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T21:37:29Z","timestamp":1633901849000},"page":"1641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2184-8919","authenticated-orcid":false,"given":"Margarita","family":"Romanenko","sequence":"first","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Laboratory of Biotechnology and Virology, Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3797-7731","authenticated-orcid":false,"given":"Ivan","family":"Osipov","sequence":"additional","affiliation":[{"name":"Laboratory of Biotechnology and Virology, Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-2464","authenticated-orcid":false,"given":"Sergey V.","family":"Netesov","sequence":"additional","affiliation":[{"name":"Laboratory of Biotechnology and Virology, Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Davydova","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA"},{"name":"Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"ref_1","unstructured":"(2021, May 31). Gene Therapy Clinical Trials (Wiley). Available online: https:\/\/a873679.fmphost.com\/fmi\/webd\/GTCT."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/07853890802021342","article-title":"Cancer, stem cells, and oncolytic viruses","volume":"40","author":"Ribacka","year":"2008","journal-title":"Ann. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1021\/mp050045c","article-title":"Genetic targeting strategies for adenovirus","volume":"2","author":"Noureddini","year":"2005","journal-title":"Mol. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1054-3589(08)60140-4","article-title":"Human adenovirus vectors for gene transfer into mammalian cells","volume":"40","author":"Hitt","year":"1997","journal-title":"Adv. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1128\/jvi.67.10.5911-5921.1993","article-title":"Packaging capacity and stability of human adenovirus type 5 vectors","volume":"67","author":"Bett","year":"1993","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.omto.2021.03.002","article-title":"Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion","volume":"20","author":"Robertson","year":"2021","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_11","unstructured":"(2021, October 05). HAdV Working Group. Available online: http:\/\/hadvwg.gmu.edu\/."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: From bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00001813-200309000-00001","article-title":"Virotherapeutics: Conditionally replicative adenoviruses for viral oncolysis","volume":"14","author":"Nettelbeck","year":"2003","journal-title":"Anticancer Drugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-20-1565","article-title":"Evolving status of clinical immunotherapy with oncolytic adenovirus","volume":"27","author":"Alemany","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Brunetti-Pierri, N. (2017). Adenovirus vector toxicity. Safety and Efficacy of Gene-Based Therapeutics for Inherited Disorders, Springer International Publishing.","DOI":"10.1007\/978-3-319-53457-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/14760584.2019.1588113","article-title":"A review of 65 years of human adenovirus seroprevalence","volume":"18","author":"Mennechet","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.virol.2010.10.041","article-title":"Characterization of species C human adenovirus serotype 6 (Ad6)","volume":"412","author":"Weaver","year":"2011","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ymthe.2005.05.008","article-title":"The influence of adenovirus fiber structure and function on vector development for gene therapy","volume":"12","author":"Nicklin","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/jcp.2003.014944","article-title":"Heterogeneity of the fibre sequence in subgenus C adenoviruses","volume":"57","author":"Adhikary","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1128\/JVI.77.13.7225-7235.2003","article-title":"Flexibility of the adenovirus fiber is required for efficient receptor interaction","volume":"77","author":"Wu","year":"2003","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1128\/jvi.68.10.6811-6814.1994","article-title":"Multiple adenovirus serotypes use alpha v integrins for infection","volume":"68","author":"Mathias","year":"1994","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: Implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1073\/pnas.0711757105","article-title":"Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo","volume":"105","author":"Kalyuzhniy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","article-title":"Adenovirus serotype 5 hexon mediates liver gene transfer","volume":"132","author":"Waddington","year":"2008","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biocel.2017.05.025","article-title":"CAR: A key regulator of adhesion and inflammation","volume":"89","author":"Santis","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_27","unstructured":"Knipe, D., and Howley, P. (2013). Adenoviridae. Fields Virology Vol.2, Wolters Kluwer\/Lippincott Williams & Wilkins Health."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/1873-3468.13794","article-title":"The coxsackievirus and adenovirus receptor: Virological and biological beauty","volume":"594","author":"Excoffon","year":"2020","journal-title":"FEBS Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-virology-092818-015550","article-title":"Adenovirus entry: From infection to immunity","volume":"6","author":"Greber","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00720-16","DOI":"10.1128\/JVI.00720-16","article-title":"Replicating single-cycle adenovirus vectors generate amplified influenza vaccine responses","volume":"91","author":"Crosby","year":"2017","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/infdis\/jiy411","article-title":"A replicating single-cycle adenovirus vaccine against Ebola virus","volume":"218","author":"Matchett","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e02016-18","DOI":"10.1128\/JVI.02016-18","article-title":"Divergent HIV-1-directed immune responses generated by systemic and mucosal immunization with replicating single-cycle adenoviruses in Rhesus macaques","volume":"93","author":"Matchett","year":"2019","journal-title":"J. Virol."},{"key":"ref_33","first-page":"847","article-title":"Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression","volume":"63","author":"Hemminki","year":"2003","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/sj.gt.3302346","article-title":"Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells","volume":"11","author":"Rivera","year":"2004","journal-title":"Gene Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-04-0064","article-title":"Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment","volume":"64","author":"Davydova","year":"2004","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/pros.21070","article-title":"Chimeric adenoviral vectors incorporating a fiber of human adenovirus 3 efficiently mediate gene transfer into prostate cancer cells","volume":"70","author":"Murakami","year":"2010","journal-title":"Prostate"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1128\/JVI.74.6.2567-2583.2000","article-title":"Efficient gene transfer into human CD34 + cells by a retargeted adenovirus vector","volume":"74","author":"Shayakhmetov","year":"2000","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Sengupta, S., Ulasov, I.V., Thaci, B., Atique, A.U., and Lesniak, M.S. (2011). Enhanced transduction and replication of RGD-fiber modified adenovirus in primary T cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018091"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1089\/10430340260201734","article-title":"Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency","volume":"13","author":"Wu","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","article-title":"Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer","volume":"157","author":"LaRocca","year":"2015","journal-title":"Surgery"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.amjsurg.2012.02.016","article-title":"Generation of a novel, Cox2-targeted, interferon-expressing, conditionally-replicative adenovirus for pancreatic cancer therapy","volume":"204","author":"Armstrong","year":"2012","journal-title":"Am. J. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1002\/ijc.29536","article-title":"Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans","volume":"137","author":"Bramante","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/JVI.72.3.1844-1852.1998","article-title":"Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob","volume":"72","author":"Krasnykh","year":"1998","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors\u2014An evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.surg.2012.02.017","article-title":"Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy","volume":"152","author":"Armstrong","year":"2012","journal-title":"Surgery"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"18041","DOI":"10.18632\/oncotarget.24710","article-title":"Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer","volume":"9","author":"Salzwedel","year":"2018","journal-title":"Oncotarget"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/cgt.2010.40","article-title":"A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma","volume":"17","author":"Sangro","year":"2010","journal-title":"Cancer Gene Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1631\/jzus.B0820248","article-title":"Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up","volume":"10","author":"Guan","year":"2009","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1038\/s41598-019-43668-8","article-title":"A tumor targeting oncolytic adenovirus can improve therapeutic outcomes in chemotherapy resistant metastatic human breast carcinoma","volume":"9","author":"Sakhawat","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/1873-3468.13649","article-title":"Interaction of adenovirus with antibodies, complement, and coagulation factors","volume":"593","author":"Allen","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2008.307","article-title":"Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver","volume":"17","author":"Shayakhmetov","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/104303403321618146","article-title":"The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors","volume":"14","author":"Liu","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.78.10.5368-5381.2004","article-title":"Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors","volume":"78","author":"Shayakhmetov","year":"2004","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/clim.2002.5266","article-title":"Visualization of the transfer reaction: Tracking immune complexes from erythrocyte complement receptor 1 to macrophages","volume":"105","author":"Craig","year":"2002","journal-title":"Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0047-6374(83)90042-8","article-title":"The reticuloendothelial system and aging: A review","volume":"21","author":"Brouwer","year":"1983","journal-title":"Mech. Ageing Dev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","article-title":"Liver sinusoidal endothelial cells\u2014Gatekeepers of hepatic immunity","volume":"15","author":"Shetty","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1189\/jlb.4VMLT0215-054R","article-title":"The liver sinusoidal endothelium reappears after being eclipsed by the Kupffer cell: A 20th century biological delusion corrected","volume":"98","author":"Anderson","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11705","DOI":"10.1128\/JVI.01320-08","article-title":"Clearance of adenovirus by kupffer cells is mediated by scavenger receptors, natural antibodies, and complement","volume":"82","author":"Xu","year":"2008","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ymthe.2005.08.007","article-title":"Rapid Kupffer cell death after intravenous injection of adenovirus vectors","volume":"13","author":"Manickan","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ganesan, L.P., Mohanty, S., Kim, J., Clark, K.R., Robinson, J.M., and Anderson, C.L. (2011). Rapid and efficient clearance of blood-borne virus by liver sinusoidal endothelium. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002281"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/10430340460732445","article-title":"Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates","volume":"15","author":"Palmer","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.immuni.2009.04.015","article-title":"Virus binding to a plasma membrane receptor triggers interleukin-1\u03b1-mediated proinflammatory macrophage response in vivo","volume":"31","author":"Miao","year":"2009","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1006\/mthe.2000.0203","article-title":"Use of quantitative TaqMan real-time PCR to track the time-dependent distribution of gene transfer vectors in vivo","volume":"2","author":"Hackett","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Koodie, L., Robertson, M.G., Chandrashekar, M., Ruth, G., Dunning, M., Bianco, R.W., and Davydova, J. (2019). Rodents versus pig model for assessing the performance of serotype chimeric Ad5\/3 oncolytic adenoviruses. Cancers, 11.","DOI":"10.3390\/cancers11020198"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00284-17","DOI":"10.1128\/JVI.00284-17","article-title":"Pathology in permissive Syrian hamsters after infection with species C human adenovirus (HAdV-C) is the result of virus replication: HAdV-C6 replicates more and causes more pathology than HAdV-C5","volume":"91","author":"Tollefson","year":"2017","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.virol.2009.08.038","article-title":"Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents","volume":"394","author":"Shashkova","year":"2009","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/mt.2011.71","article-title":"Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer","volume":"19","author":"Khare","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1128\/JVI.05760-11","article-title":"Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors","volume":"86","author":"Khare","year":"2012","journal-title":"J. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/mt.2012.287","article-title":"SR-A and SREC-I are Kupffer and endothelial cell receptors for helper-dependent adenoviral vectors","volume":"21","author":"Piccolo","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1099\/vir.0.83495-0","article-title":"Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages","volume":"89","author":"Haisma","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/mp8000974","article-title":"Scavenger receptor A: A new route for adenovirus 5","volume":"6","author":"Haisma","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1158\/1535-7163.MCT-12-0157","article-title":"MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer","volume":"11","author":"Zhang","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/bj2660313","article-title":"Scavenger functions of the liver endothelial cell","volume":"266","author":"Smedsrod","year":"1990","journal-title":"Biochem. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2006-06-032524","article-title":"Adenovirus-induced thrombocytopenia: The role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance","volume":"109","author":"Othman","year":"2007","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bradshaw, A.C., Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., K\u00e4h\u00e4ri, V.M., Nicklin, S.A., and Baker, A.H. (2010). Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001142"},{"key":"ref_79","unstructured":"Tian, J., Xu, Z., and Byrnes, A.P. (2019, January 28). Serotype-specific binding of prothrombin to adenovirus vectors. Proceedings of the ASGCT19, Washington, DC, USA."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Harmon, A.W., Moitra, R., Xu, Z., and Byrnes, A.P. (2018). Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192353"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1128\/JVI.01392-12","article-title":"Circulating Antibodies and Macrophages as Modulators of Adenovirus Pharmacology","volume":"87","author":"Khare","year":"2013","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: Lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/jvi.62.7.2321-2328.1988","article-title":"Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms","volume":"62","author":"Wohlfart","year":"1988","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1128\/JVI.00728-12","article-title":"Regulation of virus neutralization and the persistent fraction by TRIM21","volume":"86","author":"McEwan","year":"2012","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/JVI.06254-11","article-title":"Adenovirus serotype 5 neutralizing antibodies target both hexon and fiber following vaccination and natural infection","volume":"86","author":"Bradley","year":"2012","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A Novel adenovirus type 6 (Ad6)-based Hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in Rhesus macaques","volume":"80","author":"Capone","year":"2006","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/cgt.2011.47","article-title":"Mining the adenovirus virome for oncolytics against multiple solid tumor types","volume":"18","author":"Chen","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.21873\/anticanres.13815","article-title":"Oncolytic effect of adenoviruses serotypes 5 and 6 against U87 glioblastoma cancer stem cells","volume":"39","author":"Romanenko","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/mto.2015.21","article-title":"Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers","volume":"3","author":"Nguyen","year":"2016","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OV.S155946","article-title":"Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer","volume":"7","author":"Nguyen","year":"2018","journal-title":"Oncolytic Virother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1099\/vir.0.83057-0","article-title":"Evidence of frequent recombination among human adenoviruses","volume":"89","author":"Lukashev","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1128\/JCM.00156-11","article-title":"Computational analysis of two species C human adenoviruses provides evidence of a novel virus","volume":"49","author":"Walsh","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.2009.082","article-title":"Infection and killing of multiple myeloma by adenoviruses","volume":"21","author":"Senac","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/hum.2011.071","article-title":"Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model","volume":"22","author":"Weaver","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/sj.gt.3301488","article-title":"Efficient infection of primitive hematopoietic stem cells by modified adenovirus","volume":"8","author":"Yotnda","year":"2001","journal-title":"Gene Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1738-6","article-title":"Tel-eVax: A genetic vaccine targeting telomerase for treatment of canine lymphoma","volume":"16","author":"Impellizeri","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.4049\/jimmunol.180.12.8126","article-title":"A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration","volume":"180","author":"Sekine","year":"2008","journal-title":"J. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/hum.2012.047","article-title":"Characterization of infectivity-enhanced conditionally replicating adenovectors for prostate cancer radiovirotherapy","volume":"23","author":"Oneal","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/0008-5472.CAN-11-2975","article-title":"Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus","volume":"72","author":"Diaconu","year":"2012","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Matchett, W.E., Malewana, G.B.R., Mudrick, H., Medlyn, M.J., and Barry, M.A. (2020). Genetic adjuvants in replicating single-cycle adenovirus vectors amplify systemic and mucosal immune responses against HIV-1 envelope. Vaccines, 8.","DOI":"10.3390\/vaccines8010064"},{"key":"ref_103","first-page":"6","article-title":"Development of novel oncolytic vector based on alternative adenovirus serotype 6 for glioblastoma and breast cancer therapy","volume":"Volume 29","author":"Romanenko","year":"2021","journal-title":"Molecular Therapy"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2020.00909","article-title":"Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines","volume":"11","author":"Coughlan","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1517\/14712598.2010.519332","article-title":"Production of adenovirus vectors and their use as a delivery system for influenza vaccines","volume":"10","author":"Vemula","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans","volume":"63","author":"Kelly","year":"2016","journal-title":"Hepatology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00144-09","article-title":"Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults","volume":"16","author":"Harro","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Weaver, E.A., Nehete, P.N., Buchl, S.S., Senac, J.S., Palmer, D., Ng, P., Sastry, K.J., and Barry, M.A. (2009). Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005059"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/v1030920","article-title":"Protection against mucosal SHIV challenge by peptide and helper-dependent adenovirus vaccines","volume":"1","author":"Weaver","year":"2009","journal-title":"Viruses"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Weaver, E.A., Nehete, P.N., Nehete, B.P., Yang, G., Buchl, S.J., Hanley, P.W., Palmer, D., Montefiori, D.C., Ferrari, G., and Ng, P. (2013). Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067574"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Matchett, E.W., Anguiano-Zarate, S., and Barry, A.M. (2018). Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses. Glob. Vaccines Immunol., 3.","DOI":"10.15761\/GVI.1000128"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Matchett, W.E., Anguiano-Zarate, S., Malewana, G.B.R., Mudrick, H., Weldy, M., Evert, C., Khoruts, A., Sadowsky, M., and Barry, M.A. (2020). A replicating single-cycle adenovirus vaccine effective against clostridium difficile. Vaccines, 8.","DOI":"10.3390\/vaccines8030470"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virol.2014.05.030","article-title":"IIIa deleted adenovirus as a single-cycle genome replicating vector","volume":"462\u2013463","author":"Crosby","year":"2014","journal-title":"Virology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JVI.02184-14","article-title":"Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines","volume":"89","author":"Crosby","year":"2015","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02228-9","article-title":"Safety, tolerability and immunogenicity of V934\/V935 hTERT vaccination in cancer patients with selected solid tumors: A phase I study","volume":"18","author":"Aurisicchio","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_118","first-page":"1","article-title":"Phase 1 studies of the safety and immunogenicity of electroporated HER2\/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors","volume":"11","author":"Chiappori","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2010.104","article-title":"A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma","volume":"18","author":"Peruzzi","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1089\/hum.2013.112","article-title":"Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma","volume":"24","author":"Gavazza","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/mt.2009.165","article-title":"Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates","volume":"17","author":"Dharmapuri","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.vaccine.2009.11.031","article-title":"Telomerase and HER-2\/neu as targets of genetic cancer vaccines in dogs","volume":"28","author":"Peruzzi","year":"2010","journal-title":"Vaccine"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:10:38Z","timestamp":1760166638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/10\/1641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":122,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["pharmaceutics13101641"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13101641","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]}}}